We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04637269
Recruitment Status : Recruiting
First Posted : November 19, 2020
Last Update Posted : November 19, 2020
Carbiogene Therapeutics Co. Ltd.
Information provided by (Responsible Party):
Xi Zhang, MD, Xinqiao Hospital of Chongqing

Brief Summary:
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are few effective treatments for MM(multiple myeloma). BCMA (B cell maturation antigen) is a promising target for malignant plasma cells. Therefore, we designed a clinical trial using anti-BCMA CAR-T cell therapy for patients with relapsed and refractory multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Biological: anti-BCMA CAR-T Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anti-BCMA CAR-T Cell Therapy for the Relapsed or Refractory Multiple Myeloma: a Multi-center, Uncontrolled Trial.
Estimated Study Start Date : November 17, 2020
Estimated Primary Completion Date : November 1, 2021
Estimated Study Completion Date : November 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: BCMA CAR-T
The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the "3 + 3" dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.
Biological: anti-BCMA CAR-T
5×10^7 /KG 15×10^7 /KG 45×10^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.

Primary Outcome Measures :
  1. Incidence of dose limiting toxicity (DLTs) [ Time Frame: within 4 weeks after infusion ]
    To characterize the safety, tolerability, and determine the recommended dosage of Anti-BCMA CAR-T Cells for the R/R Multiple Myeloma

  2. Incidence and severity of AEs and SAEs [ Time Frame: Up to 24 months ]
    To characterize the safety, tolerability, and determine the recommended dosage of Anti-BCMA CAR-T Cells for the R/R Multiple Myeloma

Secondary Outcome Measures :
  1. Best Overall Response [ Time Frame: up to 24 months after infusion ]
    Response assessed by International Myeloma Working Group (IMWG) criteria

  2. Duration of Response [ Time Frame: up to 24 months after infusion ]
    Response assessed by International Myeloma Working Group (IMWG) criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects must meet the following criteria for inclusion in the study: 1) Male or female subjects between the ages of 18 and 75(including critical values); 2) Subjects histologically confirmed as relapsed and refractory multiple myeloma.

Positive expression of BCMA(>50%) in malignant plasma cells; Approved anti-tumor therapies, such as systemic chemotherapy, systemic radiotherapy, and immunotherapy, have been completed for at least 2 weeks before the precondition.

ECOG≤1; Life expectancy ≥ 3 months; Neutrophil absolute count ≥ 1×10^9/L; platelet count ≥ 50×10^9/L; Absolute lymphocyte count ≥ 1×10^8/L ;

Adequate organ function reserve :

GPT, GST ≤ 2.5× UNL(upper normal limit); Creatinine clearance (Cockcroft Gault method)≥60mL/min; Serum total bilirubin ≤1.5× UNL; The left ventricular ejection fraction (LVEF) ≥ 50% was diagnosed by echocardiography, and there was no clinically significant pericardial effusion and ECG abnormality; Basic oxygen saturation in indoor natural air environment > 92%; It can establish the venous access needed for collection without the contraindications of leukocyte collection; For female subjects of childbearing age, results are negative in urine pregnancy test before screening and administration, and subjects agree to take effective contraceptive measures at least one year after infusion; Male subjects with partners' fertility must agree to use effective barrier contraceptive methods at least one year after infusion, and avoid sperm donation; Voluntary signing of informed consent;

Exclusion Criteria:

Any of the following points shall be deemed as no entry into this study:

Other tumors except cured non-melanoma skin cancer, cervical cancer in situ, superficial bladder cancer, breast duct cancer in situ, or other malignant tumors with complete remission of more than 5 years); Severe mental disorders; A history of genetic diseases such as Fanconi anemia, Shudder-Dale syndrome, Costman syndrome, or any other known bone marrow failure syndrome; Heart disease with grade III-IV heart failure [NYHA classification], myocardial infarction, angioplasty or stenting, unstable angina or other heart diseases with prominent clinical symptoms within one year before admission; Subjects with any indwelling catheter or drainage tube (such as percutaneous nephrostomy tube, bile drainage tube or pleura/peritoneum/pericardium catheter), should be excluded. (Special central venous catheter is allowed); Subjects with a history of CNS lymphoma, CSF malignant cells, or brain metastasis; Subjects with a history of CNS disease,such as epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving CNS; Any of the following virological ELISA results are positive: HIV antibody, HCV antibody, TPPA, HBsAg; Active infection requiring systematic treatment within 2 weeks before single collection; Subjects with known severe allergic reactions to cyclophosphamide or fludarabine, or diagnosed as the allergy; History of autoimmune diseases (e.g. Crohn disease, rheumatoid arthritis, systemic lupus erythematosus) that cause end-organ damage or require systemic immunosuppressive medications or systemic disease modifying drugs in the past 2 years; Presence of pulmonary fibrosis; Subjects who have received other clinical trial treatment within 4 weeks before participating in this trial should be excluded. Or the signing date of informed consent is within 5 half-lives of the last application of another clinical trial (whichever is longer); Subjects with poor compliance due to physiological, family, social, geographical and other factors, or those unable to cooperate with the study plan or follow-up; At the discretion of the investigator, there are complications requiring systemic corticosteroid therapy (≥ 5mg / day of prednisone or equivalent dose of other corticosteroids) or other immunosuppressive drugs within 6 months after this clinical research treatment; The lactating woman who is reluctant to stop breastfeeding; Any other condition considered unsuitable by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04637269

Layout table for location contacts
Contact: Xi Zhang, MD phD 13808310064 ext +86 zhangxxi@sina.com
Contact: Ruihao Huang 18984398751 ext +86 1169731117@qq.com

Layout table for location information
China, Chongqing
Department of Hematology, Xinqiao Hospital Recruiting
ChongQing, Chongqing, China, 400037
Contact: Xi Zhang, MD    +8613808310064 ext +8613808310064    zhangxxi@sina.com   
Contact: Ruihao Huang    +8618984398751 ext +8618984398751    1169731117@qq.com   
Sponsors and Collaborators
Xinqiao Hospital of Chongqing
Carbiogene Therapeutics Co. Ltd.
Layout table for investigator information
Study Chair: Xi Zhang Xinqiao Hospital of Chongqing
Layout table for additonal information
Responsible Party: Xi Zhang, MD, Chef of Hematology Department, Xinqiao Hospital of Chongqing
ClinicalTrials.gov Identifier: NCT04637269    
Other Study ID Numbers: BCMA CAR-T cell
First Posted: November 19, 2020    Key Record Dates
Last Update Posted: November 19, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases